The commercial formulation of fast dispersing dosage form (FDDF) needs a large amount of retention time, and high amount of drug active material is formed as single dose unit during this period. During this retention time, the drug agent in water environment with polymorphic sexual orientation may crystallize into various, sometimes uncertain form. These crystal forms may influence the effect of medicament. The trial for attempting to control this process in the past includes that will crystallize to be translates directly into stable form. The present invention inhibits to crystallize by the combination using standard molecular weight isinglass and low processing temperature, to being suppressed to crystallization using standard molecular weight isinglass or all inaccessiable degree of low processing temperature. Individual temperature.
